ZYLOX-TONBRDG.MED.TECH.H1 (818) — Working Capital to Net Assets Ratio
ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Working Capital to Net Assets ratio of 48.8% as of June 2025. Working capital of €1.54 Billion (current assets of €1.86 Billion minus current liabilities of €323.03 Million) is measured against net assets of €3.15 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See ZYLOX-TONBRDG.MED.TECH.H1 (818) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
ZYLOX-TONBRDG.MED.TECH.H1 Working Capital to Net Assets (2021–2024)
This chart shows how ZYLOX-TONBRDG.MED.TECH.H1's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of June 2025, the ratio stands at 48.8%, reflecting working capital of €1.54 Billion against net assets of €3.15 Billion EUR. For the complete balance sheet picture, see ZYLOX-TONBRDG.MED.TECH.H1 balance sheet assets.
Annual Working Capital to Net Assets for ZYLOX-TONBRDG.MED.TECH.H1 (2021–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for ZYLOX-TONBRDG.MED.TECH.H1 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check ZYLOX-TONBRDG.MED.TECH.H1 liquid asset ratio to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 38.5% | €1.19 Billion | €3.10 Billion | €1.53 Billion | €334.17 Million | ▼ -7.4 pp |
| 2023 | 45.9% | €1.40 Billion | €3.05 Billion | €1.72 Billion | €317.78 Million | ▼ -15.8 pp |
| 2022 | 61.7% | €1.91 Billion | €3.09 Billion | €2.06 Billion | €152.08 Million | ▼ -31.3 pp |
| 2021 | 93.1% | €2.93 Billion | €3.14 Billion | €3.02 Billion | €97.10 Million | — |